Abstract
Heparin affin regulatory peptide (HARP), also known as pleiotrophin or heparin-binding growthassociated molecule, is an 18-kDa growth factor that has a high affinity for heparin. It constitutes with midkine and retinoic acid heparin-binding protein, a family of structurally related heparin-binding growth factors. A growing body of evidence indicates that HARP is involved in the control of cellular proliferation, migration and differentiation and plays a significant role in tumor growth and angiogenesis. HARP has a well described role in physiological as well as tumor angiogenesis, and is detected in various carcinomas, such as human breast and prostate cancer, neuroblastomas, gliomas, benign meningiomas, small cell lung cancer and mammary tumors, exhibiting a proto-oncogene function. It is also constitutively expressed in tumour cell lines and is involved in tumour growth and metastasis. Therefore, HARP appears to be a potential new target for the treatment or / and diagnosis of several types of cancer.
Keywords: heparin affin regulatory peptide, pleiotrophin, angiogenesis, cancer, growth factors
Current Cancer Drug Targets
Title: Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Volume: 4 Issue: 6
Author(s): E. Papadimitriou, A. Polykratis, M. Hatziapostolou, A. Parthymou, C. Polytarchou and C. Mikelis
Affiliation:
Keywords: heparin affin regulatory peptide, pleiotrophin, angiogenesis, cancer, growth factors
Abstract: Heparin affin regulatory peptide (HARP), also known as pleiotrophin or heparin-binding growthassociated molecule, is an 18-kDa growth factor that has a high affinity for heparin. It constitutes with midkine and retinoic acid heparin-binding protein, a family of structurally related heparin-binding growth factors. A growing body of evidence indicates that HARP is involved in the control of cellular proliferation, migration and differentiation and plays a significant role in tumor growth and angiogenesis. HARP has a well described role in physiological as well as tumor angiogenesis, and is detected in various carcinomas, such as human breast and prostate cancer, neuroblastomas, gliomas, benign meningiomas, small cell lung cancer and mammary tumors, exhibiting a proto-oncogene function. It is also constitutively expressed in tumour cell lines and is involved in tumour growth and metastasis. Therefore, HARP appears to be a potential new target for the treatment or / and diagnosis of several types of cancer.
Export Options
About this article
Cite this article as:
Papadimitriou E., Polykratis A., Hatziapostolou M., Parthymou A., Polytarchou C. and Mikelis C., Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?, Current Cancer Drug Targets 2004; 4 (6) . https://dx.doi.org/10.2174/1568009043332835
DOI https://dx.doi.org/10.2174/1568009043332835 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Alcoholic Bark Extract of <i>Terminalia Arjuna</i> Exhibits Cytotoxic and Cytostatic Activity on Jurkat Leukemia Cells
Venoms and Toxins An Update on Overcoming MDR1-Mediated Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Design Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and Anti-Angiogenic/Lymphangiogenic Effect
Current Pharmaceutical Biotechnology Update on Laser Photochemotherapy: An Alternative for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Metabotropic Glutamate Receptor Ligands as Potential Therapeutics for Addiction
Current Drug Abuse Reviews The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews Glycans in Magnetic Resonance Imaging: Determinants of Relaxivity to Smart Agents, and Potential Applications in Biomedicine
Current Medicinal Chemistry Targeting Long Non-Coding RNAs in Nervous System Cancers: New Insights in Prognosis, Diagnosis and Therapy
Current Medicinal Chemistry mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area
Current Psychiatry Reviews Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets Anti-breast Cancer Agents, Quinolines, Targeting Gap Junction
Medicinal Chemistry Kinins and Cardiovascular Diseases
Current Pharmaceutical Design The Metastatic Process: Methodological Advances and Pharmacological Challenges
Current Medicinal Chemistry High Throughput Screening for Drug Discovery of Autophagy Modulators
Combinatorial Chemistry & High Throughput Screening Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging Physiological Functions of Presenilins; Beyond γ-Secretase
Current Pharmaceutical Biotechnology